Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats moderately to severely active rheumatoid arthritis. Sold as Kevzara. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Sarilumab (sold as Kevzara), first approved May 22, 2017, with 3 new uses approved and 0 published complete response letters.
First approved: May 22, 2017
Applications: 1
New uses approved: 3
Complete response letters: 0
Medicare spending, 2025: $303M
First approved in the EU: Jun 23, 2017
First approved in Japan: Sep 27, 2017
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 4 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Kevzara, new ingredientDrugs with a new active ingredient indicated for the treatment of rheumatoid arthritis in patients who have not responded sufficiently to conventional… · Sanofi K.K. · Sep 27, 2017 · Review report
Clinical Trials
21 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
